ReviewExpert review of anti-infective therapy2014
Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States.
Review in Expert review of anti-infective therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 100 citations in OpenAlex.
- Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.BMC infectious diseases · 2017Trial
- Risk factors associated with carbapenem-resistant Gram-negative bacterial infections in intensive care units in Jordan.BMC infectious diseases · 2026Article
- Carbapenem-resistantbioRxiv : the preprint server for biology · 2026Article
- Trends in urolithiasis mortality in the United States, 1999-2024: a Joinpoint regression analysis of age, sex, race, and regional disparities.Frontiers in surgery · 2026Article
- Nanotechnology Meets superbugs: biocompatible polymeric nanoparticles combat MDR Klebsiella pneumoniae via gene suppression and biofilm Inhibition.Scientific reports · 2025Article
- Urinary Tract Infections Caused by Extended-Spectrum Beta-Lactamase-Producing and Carbapenem-Resistant Enterobacterales in Saudi Arabia: Impact of Catheterization.Medicina (Kaunas, Lithuania) · 2025Article
- Insights into the Metabolic Adaptations of a Carbapenem-ResistantInternational journal of molecular sciences · 2025Article
- Characterization of carbapenem-resistant Enterobacterales andJournal of clinical microbiology · 2024Article
- Epidemiology of carbapenem-resistant organisms in Alameda County, California, 2019-2021.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Genomic insights and antimicrobial resistance profiles of CRKP and non-CRKP isolates in a Beijing geriatric medical center: emphasizing theFrontiers in microbiology · 2024Article
- Clonal Lineages and Virulence Factors of Carbapenem ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Epidemiology and Early Bacteriology of Extremely Severe Burns from an LPG Tanker Explosion in Eastern China.Journal of epidemiology and global health · 2022Article
- Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2022Review
- Demographic, clinical, and outcome characteristics of carbapenem-resistant Enterobacteriaceae over a 10-year period (2010-2020) in Oman.IJID regions · 2022Article
- Article
- Risk Factors for a Hospital-Acquired Carbapenem-ResistantInfection and drug resistance · 2022Article
- Major infections following pediatric cardiac surgery pre- and post-CLABSI bundle implementation.PeerJ · 2022Article
- A Nomogram With Six Variables Is Useful to Predict the Risk of Acquiring Carbapenem-Resistant Microorganism Infection in ICU Patients.Frontiers in cellular and infection microbiology · 2022Article
- Prevalence of Carbapenem-ResistantInfection and drug resistance · 2022Article
- Carbapenem Resistance among Marine Bacteria-An Emerging Threat to the Global Health Sector.Microorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Carbapenem-resistant Enterobacteriaceae (CRE) are multidrug-resistant organisms with few treatment options that cause infections associated with substantial morbidity and mortality. CRE outbreaks have been increasingly reported worldwide and are mainly due to the emergence and spread of strains that produce carbapenemases. In the United States, transmission of CRE is primarily driven by the spread of organisms carrying the Klebsiella pneumoniae carbapenemase enzyme, but other carbapenemase enzymes, such as the New-Delhi metallo-β-lactamase, have also emerged. Currently recommended control strategies for healthcare facilities include the detection of patients infected or colonized with CRE and implementation of measures to prevent further spread. In addition to efforts in individual facilities, effective CRE control requires coordination across all healthcare facilities in a region. This review describes the current epidemiology and surveillance of CRE in the United States and the recommended approach to prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.